PAINADATH v. GOOD SHEPHERD PENN PARTNERS

CourtDistrict Court, E.D. Pennsylvania
DecidedJuly 19, 2023
Docket2:22-cv-03604
StatusUnknown

This text of PAINADATH v. GOOD SHEPHERD PENN PARTNERS (PAINADATH v. GOOD SHEPHERD PENN PARTNERS) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
PAINADATH v. GOOD SHEPHERD PENN PARTNERS, (E.D. Pa. 2023).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA JERRY J. PAINADATH, Plaintiff, CIVIL ACTION v. NO. 22-3604 MELISSA LATTANZIO, et al., Defendants. PAPPERT, J. July 19, 2023 MEMORANDUM Nurse Jerry Painadath, proceeding pro se, alleges in his Amended Complaint that his former employer, Philadelphia Post-Acute Partners, LLC d/b/a Good Shepherd Penn Partners (“GSPP”), and three of its employees retaliated against him for reporting patient safety concerns. He sued employees Melissa Lattanzio, Natalie Blanden and Tiana Belton (the individual defendants) for violations of the Racketeer Influenced and Corrupt Organizations Act (“RICO”), 18 U.S.C. § 1964; Lattanzio and Blanden for violations of the Pennsylvania Professional Nursing Law, 63 P.S. § 211; and GSPP for violations of the Affordable Care Act (“ACA”), 42 U.S.C. § 18116 & 29 U.S.C. § 218c;

Title VII, 42 U.S.C. § 2000e et seq.; and the Pennsylvania Older Adults Protective Services Act (“OAPSA”), 35 P.S. § 10225.101 et seq. The defendants move to dismiss the Amended Complaint. (ECF 21.) After considering the Motion and all responses and replies, (ECF 22, 23, 24), the Court grants Defendants’ motion. Painadath’s RICO and Professional Nursing Law claims against the individual defendants are dismissed with prejudice, and his claims against GSPP are dismissed without prejudice. I GSPP employed Painadath as a “clinical nurse 2” from July of 2020 until December of 2021. (Am. Compl. ¶¶ 28, 37, 62.) Painadath alleges that he reported several patient safety-related incidents during his tenure, and that GSPP became

increasingly hostile toward him as a result. (Id. at ¶ 47.) On May 14, 2021, Painadath says that he found a “full vial of Naropin,” an anesthetic, on a patient’s bedside table. (Id. at ¶ 44.) Believing the drug to be “lethal,” he removed it from the table, “destroyed it,” and reported the incident internally. (Id. at ¶ 45.) Painadath claims that in August of 2021 he was “left with notice” for reporting to management that “CNA Crystal” assaulted him and used excessive force on a patient. (Id. at ¶¶ 53–55.) He alleges that on September 30, 2021, he was suspended for reporting “an older African American patient’s neglect” by “CNA Jasmine.” (Id. at

¶ 58.) On December 14, 2021, Painadath was terminated, allegedly for filing an ACA violation complaint with OSHA on December 5, 2021. (Id. at ¶¶ 61–62, 74.) He also claims GSPP retaliated against him for filing the ACA complaint by “ostraciz[ing]” him from other healthcare employers in the area, although he began working for Kindred Hospital in January of 2022. (Id. at ¶¶ 64, 75.) II A motion to dismiss under Rule 12(b)(6) tests the sufficiency of the factual allegations in the complaint. Kost v. Kozakiewicz, 1 F.3d 176, 183 (3d Cir. 1993). When confronted with a 12(b)(6) motion, a district court must conduct a two-step analysis. Fowler v. UPMC Shadyside, 578 F.3d 203, 210 (3d Cir. 2009). First, the Court “must accept all of the complaint’s well-pleaded facts as true, but may disregard any legal conclusions.” Id. at 210–11. It “must then determine whether the facts alleged in the complaint are sufficient to show that the plaintiff has a ‘plausible claim for relief.’” Id. at 211 (quoting Ashcroft v. Iqbal, 556 U.S. 662, 679 (2009)). The Court must “construe

the complaint in the light most favorable to the plaintiff . . . .” Phillips v. Cnty. of Allegheny, 515 F.3d 224, 231 (3d Cir. 2008) (quoting Pinker v. Roche Holdings Ltd., 292 F.3d 361, 374 n.7 (3d Cir. 2002)). Pro se litigants’ pleadings must be liberally construed, although they “still must allege sufficient facts in their complaints to support a claim.” Mala v. Crown Bay Marina, Inc., 704 F.3d 239 (3d Cir. 2013). III A Painadath claims Lattanzio, Blanden and Belton violated the RICO statute. To state a civil RICO claim under 18 U.S.C. § 1962(c), a plaintiff must allege “(1) conduct

(2) of an enterprise (3) through a pattern (4) of racketeering activity.” Warden v. McLelland, 288 F.3d 105, 114 (3d Cir. 2002) (quoting Sedima, S.P.R.L. v. Imrex Co., 473 U.S. 479, 496 (1985)).1 “Racketeering activity” is defined by an enumerated list of predicate acts under 18 U.S.C. § 1961(1). A RICO plaintiff must show that the defendant committed two or more predicate acts within a ten-year period to establish the requisite pattern of racketeering activity. 18 U.S.C. § 1961(5). The alleged predicate acts upon which Painadath ostensibly relies are his claims that the three individual defendants violated 18 U.S.C. § 229 (relating to chemical

1 Painadath does not specify which subsection of 18 U.S.C. § 1962 he is invoking. Because there is no indication that Lattanzio, Blanden or Belton controlled, invested in, or had an interest in an enterprise engaged in interstate or foreign commerce, the Court will analyze his claim under § 1962(c), which applies to employees and associates of an enterprise engaged in interstate or foreign commerce. weapons), 18 U.S.C. § 1503 (obstruction of justice) and 18 U.S.C. § 1591 (sex trafficking of children).2 He also claims that Lattanzio violated 18 U.S.C. § 664 (embezzlement from pension and welfare funds). 18 U.S.C. § 229 implements the international Convention on Chemical Weapons

and “makes it a federal crime for a person to use or possess any chemical weapon.” Bond v. United States, 572 U.S. 844, 847 (2014). Painadath alleges that he found a “full vial” of the anesthetic Naropin on a patient’s bedside table, and that the FDA warns that “rapid accidental administration” of Naropin can cause cardiac arrest. This is insufficient for several reasons. First, Painadath does not allege that Lattanzio, Blanden or Belton possessed the Naropin. Second, many medications have harmful— even lethal—effects if improperly administered. That does not make them chemical weapons. Toxic chemicals possessed for peaceful purposes—including medical purposes—are not “chemical weapons.” 18 U.S.C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Sedima, S. P. R. L. v. Imrex Co.
473 U.S. 479 (Supreme Court, 1985)
United States v. Aguilar
515 U.S. 593 (Supreme Court, 1995)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Kost v. Kozakiewicz
1 F.3d 176 (Third Circuit, 1993)
Kelley Mala v. Crown Bay Marina
704 F.3d 239 (Third Circuit, 2013)
United States v. Barry Sussman
709 F.3d 155 (Third Circuit, 2013)
Phillips v. County of Allegheny
515 F.3d 224 (Third Circuit, 2008)
Fowler v. UPMC SHADYSIDE
578 F.3d 203 (Third Circuit, 2009)
Spierling v. First American Home Health Services, Inc.
737 A.2d 1250 (Superior Court of Pennsylvania, 1999)
McLaughlin v. Gastrointestinal Specialists, Inc.
750 A.2d 283 (Supreme Court of Pennsylvania, 2000)
Hennessy v. Santiago
708 A.2d 1269 (Superior Court of Pennsylvania, 1998)
Diberardinis-Mason v. Super Fresh
94 F. Supp. 2d 626 (E.D. Pennsylvania, 2000)
Bond v. United States
134 S. Ct. 2077 (Supreme Court, 2014)
Roger Wilson v. EI DuPont de Nemours & Co
710 F. App'x 57 (Third Circuit, 2018)
John Doe v. BlueCross BlueShield of Tenn., Inc.
926 F.3d 235 (Sixth Circuit, 2019)
John Doe v. University of the Sciences
961 F.3d 203 (Third Circuit, 2020)
Warden v. McLelland
288 F.3d 105 (Third Circuit, 2002)
Tanay v. Encore Healthcare, LLC
810 F. Supp. 2d 734 (E.D. Pennsylvania, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
PAINADATH v. GOOD SHEPHERD PENN PARTNERS, Counsel Stack Legal Research, https://law.counselstack.com/opinion/painadath-v-good-shepherd-penn-partners-paed-2023.